Proteinuria Therapeutics Market – The increase in the prevalence of chronic kidney disease, a major cause of proteinuria is expected to drive the growth of the market
Proteinuria is defined as an increase in protein levels in the urine. The condition of proteinuria is often a sign of kidney disease. Kidneys are bean-shaped organs, whose main function is to filter blood. The kidney contains blood vessels called glomeruli, which remove waste from the urine and reabsorb protein from the blood. However, if the kidneys or glomeruli gets damaged, the proteins such as albumin may accidently enter the urine. Hence, this leads to high protein levels in urine that is proteinuria. A progressive decline in kidney function might eventually require dialysis or a kidney transplant. Diabetes and high blood pressure, both can harm the kidneys and are the leading causes of kidney disease.
Proteinuria is frequently caused by relatively benign (non-cancerous) or temporary medical conditions including dehydration, inflammation, and low blood pressure. Proteinuria might also occur due to intense exercise or activity, emotional stress, aspirin therapy, and exposure to cold temperatures.
Some common symptoms of proteinuria include frequent urination, shortness of breath, tiredness, nausea, and lack of appetite. Proteinuria can be diagnosed and detected by a 24 hour urine test, glomerular filtrate rate (GMR) blood test, ultrasound or computed tomography (CT) scan, and kidney biopsy.
The treatment is determined by the underlying condition that caused the proteinuria. Each condition requires different treatment plans. For example, if kidney disease is diagnosed, a treatment plan may consist of medication such as diuretics, dietary changes, weight loss, and exercise. Patients with diabetes and hypertension who have proteinuria may require blood pressure medication such as angiotensin-converting enzyme (ACE) inhibitors, and those with diabetes might need to control their blood sugar level.
Buy Now this Premium Report to Grow your Business: https://www.coherentmarketinsights.com/insight/buy-now/4491
Reasons to Purchase this Report
• Current and future of global Proteinuria Therapeutics market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
“Limited Time Offer”
Access insightful study with over 150+ pages, list of tables & figures, profiling 20+ companies.
We also offer 15% FREE Report customization.
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/4491
Global Proteinuria Therapeutics Market – Dynamics
The increase in prevalence of chronic kidney disease, a major cause of proteinuria is expected to drive growth of the global proteinuria therapeutics market. For instance, according to the Centers for Disease Control and Prevention, in March 2021, over one in seven, accounting for 37 million people (15% of the adults), are estimated to have chronic kidney disease in the U.S. Moreover, according to the same source, Chronic kidney disease was found to be more prevalent in people aged 65 years or older (38%) compared to people aged 45–64 years (12%) or 18-44 years (6%).
The increasing clinical development of drugs for the treatment of chronic kidney disease and proteinuria is expected to boost global proteinuria therapeutics market growth. For instance, on June 06, 2021, Novartis, a global healthcare company, revealed their Phase II primary endpoint data demonstrating that investigational ‘iptacopan’ reduced protein in the urine (proteinuria), a key risk predictor associated with progression of kidney failure. Iptocan is a first-in-class, oral, targeted factor B inhibitor, which also showed a stabilizing kidney function in patients with IgA nephropathy.
The rising mergers, agreements, and acquisitions by market players are expected to propel growth of the global proteinuria therapeutics market over the forecast period. For instance, on January 10, 2020, Chinook Therapeutics Inc., a biotechnology firm focused on developing precision medicines for kidney diseases, announced a license agreement with AbbVie, a research-based global biopharmaceutical company, for worldwide exclusive rights to ‘atrasentan’, an endothelin receptor antagonist. Atrasentan is being developed for the treatment of primary glomerular diseases, which are characterized by proteinuria. These factors are expected to support global proteinuria therapeutics market growth over the forecast period.
Global Proteinuria Therapeutics Market – Regional Insights
Among regions, North America is expected to account for the largest share in global proteinuria therapeutics market over the forecast period, owing to the submission of new drug applications for the treatment of proteinuria associated diseases such as nephropathy. For instance, on March 15, 2021, Calliditas Therapeutics AB officially confirmed the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Nefecon, a novel oral formulation targeting IgA1 down regulation for the treatment of primary IgA Nephropathy (IgAN). Nefecon in the part A of phase III study met its primary endpoint of lowering proteinuria compared to placebo, as well as stabilizing estimated glomerular filtration rate (eGFR) at nine months. Calliditas Therapeutics is a specialty pharmaceutical company, which focuses on developing novel treatments for orphan indications, with an initial focus on renal and hepatic diseases.
Ask for PDF sample copy of the Proteinuria Therapeutics market report @ https://www.coherentmarketinsights.com/insight/request-pdf/4491
Moreover, due to recent drug approvals by regulatory authorities for the treatment of proteinuria associated diseases such as lupus nephritis, Europe may witness a lucrative growth in global proteinuria therapeutics market over the forecast period. For instance, on May 05, 2021, GlaxoSmithKline plc. (GSK), a science-led global healthcare company announced that the European Commission approved the expanded use of intravenous BENLYSTA (belimumab) in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis (LN) in Europe. Proteinuria is one of the manifestations of lupus nephritis. BENLYSTA, a BLyS-specific inhibitor, is a human monoclonal antibody that binds to soluble BLyS. These factors are expected to support global proteinuria therapeutics market growth over the forecast period.
Global Proteinuria Therapeutics Market–Taxonomy
By Drug Class:
- Angiotensin-converting Enzyme (ACE) Inhibitors
- Angiotensin II Receptor Antagonists (ARBs)
By Route of Administration:
By Distribution Channels:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Asia Pacific
- Latin America
- Middle East
Global Proteinuria Therapeutics Market – Competitive landscape
Key players operating in the global proteinuria therapeutics market include GlaxoSmithKline plc, Chinook Therapeutics Inc., Novartis International AG, AbbVie Inc., Calliditas Therapeutics AB, Travere Therapeutics Inc., Walden Biosciences, Ligand Pharmaceuticals Inc., and Retrophin, Inc.
Major Point Answered in Proteinuria Therapeutics Market Research Study are: –
• What will the market growth rate, Overview and Analysis by Type of Proteinuria Therapeutics market in 2026?
• What are the key factors driving, Analysis by Applications and Countries Proteinuria Therapeutics market?
• What are Dynamics, This Overview Includes Analysis of Scope, and price analysis of top Manufacturers Profiles of Proteinuria Therapeutics market?
• Who are Opportunities, Risk and Driving Force of Proteinuria Therapeutics market? Knows Upstream Raw Materials Sourcing and Downstream Buyers
• Who are the key vendors in Proteinuria Therapeutics market space? Business Overview by Type, Applications, Gross Margin and Market Share
• What are the Proteinuria Therapeutics market opportunities and threats faced by the vendors in the market?
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire